Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer

NCT07480356 is registered in ClinicalTrials.gov with Protara Therapeutics as lead sponsor.

NCT NCT07480356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07480356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer
Lead sponsor
Protara Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
May 29, 2026
Completion date
November 30, 2032
Enrollment
284 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

bladder (urothelial, transitional cell) cancer, non-muscle invasive bladder cancer with carcinoma in situ, non-muscle invasive bladder carcinoma